On the road to biological blood diagnosis of Alzheimer's disease?


Por: Delaby, C, Lehmann, S

Publicada: 23 abr 2024
Resumen:
The growing number of people suffering from Alzheimer's disease (AD) represents a major public health problem. The diagnosis of AD is multidisciplinary and involves the use of amyloid and tau biomarkers measured in cerebrospinal fluid. Recent advances in analytical techniques now allow us to measure these biomarkers in blood. Blood biomarkers offer particularly promising potential for early, minimally invasive detection of AD, as well as for differential diagnosis of dementia and patient follow-up. The aim of this review is to provide an overview of current and candidate blood biomarkers for AD, their informative value, and their potential to be integrated into clinical practice in the near future.

Filiaciones:
Delaby, C:
 Univ Montpellier, LBPC PPC, CHU Montpellier, INM Inserm U1298, Montpellier, France

 Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Biomed Res Inst St Pau, Barcelona, Spain

Lehmann, S:
 Univ Montpellier, LBPC PPC, CHU Montpellier, INM Inserm U1298, Montpellier, France
ISSN: 07670974
Editorial
EDP SCIENCES S A, 17, AVE DU HOGGAR, PA COURTABOEUF, BP 112, F-91944 LES ULIS CEDEX A, FRANCE, Francia
Tipo de documento: Article
Volumen: 40 Número: 4
Páginas:
WOS Id: 001206755400006
ID de PubMed: 38651960
imagen Green Submitted, hybrid

MÉTRICAS